Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial

INTRODUCTION: Benign prostatic hyperplasia (BPH) is common in men 50 years old and older. The main treatment options are alpha-blockers (such as tamsulosin), which reduce symptoms, and 5-alpha reductase inhibitors (such as dutasteride), which reduce symptoms and slow disease progression. Clinical st...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ismaila, Afisi, Walker, Anna, Sayani, Amyn, Laroche, Bruno, Nickel, J. Curtis, Posnett, John, Su, Zhen
Format: Artigo
Idioma:Inglês
Publicat: Canadian Medical Association 2013
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3699085/
https://ncbi.nlm.nih.gov/pubmed/23826050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.12131
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars